Featured Publications
Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials
Lydecker JA, Grilo CM. Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials. Psychological Medicine 2021, 52: 4085-4093. PMID: 33849682, PMCID: PMC8514588, DOI: 10.1017/s0033291721001045.Peer-Reviewed Original ResearchBinge-eating disorderBinge-eating frequencyEating-disorder psychopathologyPsychiatric comorbidityBED treatment outcomesCognitive behavioral therapySelf-report measuresModerators of outcomeBinge-eating remissionDisorder treatment outcomesBehavioral weight lossRandomized-controlled trialCurrent psychiatric comorbidityMore effective interventionsTreatment outcomesAnxiety disordersTreatment researchSemi-structured interviewsMood comorbiditiesControl conditionPsychopathologyEffective interventionsComorbidity effectsWeight lossCurrent studyExamining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials
Lydecker JA, Gueorguieva R, Masheb R, White MA, Grilo CM. Examining Race as a Predictor and Moderator of Treatment Outcomes for Binge-Eating Disorder: Analysis of Aggregated Randomized Controlled Trials. Journal Of Consulting And Clinical Psychology 2019, 87: 530-540. PMID: 31008634, PMCID: PMC6589831, DOI: 10.1037/ccp0000404.Peer-Reviewed Original ResearchConceptsBinge-eating disorderWhite participantsCognitive behavioral therapySelf-report measuresTreatment outcomesBinge-eating remissionModerate treatment outcomeBinge Eating DisorderBinge-eating episodesMain effectBlack participantsWeight lossBehavioral weight lossEvidence-based treatmentsLower depressionTreatment researchRandomized Controlled TrialsBetter treatment outcomesControl conditionParticipantsControlled TrialsMultimodal treatmentPercent weight lossPatient groupModerator
2023
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlacebo
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures